[go: up one dir, main page]

WO2000066101A3 - Method of inhibiting glycation product formation - Google Patents

Method of inhibiting glycation product formation Download PDF

Info

Publication number
WO2000066101A3
WO2000066101A3 PCT/US2000/011354 US0011354W WO0066101A3 WO 2000066101 A3 WO2000066101 A3 WO 2000066101A3 US 0011354 W US0011354 W US 0011354W WO 0066101 A3 WO0066101 A3 WO 0066101A3
Authority
WO
WIPO (PCT)
Prior art keywords
product formation
glycation product
disease
products
advanced glycation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/011354
Other languages
French (fr)
Other versions
WO2000066101A2 (en
Inventor
Jerry L Nadler
Samuel Rahbar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Priority to AU46711/00A priority Critical patent/AU4671100A/en
Publication of WO2000066101A2 publication Critical patent/WO2000066101A2/en
Anticipated expiration legal-status Critical
Publication of WO2000066101A3 publication Critical patent/WO2000066101A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a method of preventing the formation of advanced glycation products through administering a xanthine-based compound, for example, lisofylline. The method is useful in treatments for diseases associated with advanced glycation end-products, such as diabetes, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Down's syndrome, osteoarthritis, cataracts, cardiac hypertrophy, arterial stiffening, atherosclerosis and kidney toxicity.
PCT/US2000/011354 1999-04-30 2000-04-28 Method of inhibiting glycation product formation Ceased WO2000066101A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46711/00A AU4671100A (en) 1999-04-30 2000-04-28 Method of inhibiting glycation product formation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13192799P 1999-04-30 1999-04-30
US60/131,927 1999-04-30

Publications (2)

Publication Number Publication Date
WO2000066101A2 WO2000066101A2 (en) 2000-11-09
WO2000066101A3 true WO2000066101A3 (en) 2002-02-14

Family

ID=22451635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011354 Ceased WO2000066101A2 (en) 1999-04-30 2000-04-28 Method of inhibiting glycation product formation

Country Status (2)

Country Link
AU (1) AU4671100A (en)
WO (1) WO2000066101A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439593C (en) * 2001-04-05 2010-02-09 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
CN109503584A (en) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 Polymorphic
US20110052625A1 (en) * 2008-01-31 2011-03-03 Diakine Therapeutics, Inc. Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
CN109310697A (en) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 Combination of linagliptin and metformin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
WO1999036073A1 (en) * 1998-01-16 1999-07-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
WO2000066128A1 (en) * 1999-04-30 2000-11-09 Cell Therapeutics, Inc. Method of enhancing insulin action

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
WO1999036073A1 (en) * 1998-01-16 1999-07-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
WO2000066128A1 (en) * 1999-04-30 2000-11-09 Cell Therapeutics, Inc. Method of enhancing insulin action

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BALON THOMAS W ET AL: "Lisofylline, a modulator of fatty acid metabolism, increases peripheral insulin sensitivity.", DIABETES, vol. 48, no. SUPPL. 1, 1999, 59th Scientific Sessions of the American Diabetes Association;San Diego, California, USA; June 19-22, 1999, pages A95, XP000997431, ISSN: 0012-1797 *
BLEICH D ET AL: "Lisofylline prevents IL-1-beta induced dysfunction of cultured rat islets.", JOURNAL OF INVESTIGATIVE MEDICINE, vol. 43, no. SUPPL. 2, 1995, Clinical Research Meeting;San Diego, California, USA; May 5-8, 1995, pages 323A, XP000997466 *
BLEICH DAVID ET AL: "Lisofylline, an inhibitor of unsaturated phosphatidic acid generation, ameliorates interleukin-1-beta-induced dysfunction in cultured rat islets.", ENDOCRINOLOGY, vol. 137, no. 11, 1996, pages 4871 - 4877, XP000997474, ISSN: 0013-7227 *
BRANDT, J. ET AL: "Beneficial effects of a drug which inhibits cytokine effects in a macrophage (M-vphi) mediated model of glomerulo-nephritis (GN).", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (1994) VOL. 5, NO. 3, PP. 776. MEETING INFO.: ABSTRACTS SUBMITTED FOR THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY ORLANDO, FLORIDA, USA OCTOBER 26-29, 1994, XP000997421 *
LINAS STUART L ET AL: "Modulation of unsaturated acyl chain metabolism protects kidneys from ischemic injury.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 9, no. PROGRAM AND ABSTR. ISSUE, 1998, 31st Annual Meeting of the American Society of Nephrology;Philadelphia, Pennsylvania, USA; October 25-28, 1998, pages 581A, XP000997422, ISSN: 1046-6673 *
MARGOLIN, KIM ET AL: "Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma", CLIN. CANCER RES. (1997), 3(4), 565-572, XP000990798 *
TROTTI A.: "Toxicity antagonists in cancer therapy.", CURRENT OPINION IN ONCOLOGY, (1997) 9/6 (569-578)., XP000997467 *

Also Published As

Publication number Publication date
AU4671100A (en) 2000-11-17
WO2000066101A2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
WO2000061568A3 (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
EP1380564A4 (en) Binaphtol derivative and process for producing the same
WO2001072728A3 (en) Novel piperazine derivatives
WO2000066101A3 (en) Method of inhibiting glycation product formation
WO2001066564A3 (en) Gamma-secretase inhibitors
BG105177A (en) Novel substituted pyrazole derivatives
WO2004024081A3 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
WO2002030882A3 (en) Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
WO2002008194A8 (en) Novel heteroaryl derivatives and the use thereof as pharmaceuticals
MY119350A (en) Propiophenone derivatives and process for preparing the same
WO2005021497A3 (en) Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
WO1999012532A3 (en) Piperidine derivatives against malaria
WO2006067103A3 (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
WO2002102787A3 (en) Novel sulfonic acid derivatives
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
EP0597112A4 (en) Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor.
WO2000046210A3 (en) New process for preparing pesticidal intermediates
IE892596L (en) Arylalkyl-amines and -amides having anticonvulsant and¹neuroprotective properties
WO2002012243A3 (en) SYNTHESIS OF (R)-3-(4-BROMOBENZYL)-1-(3,5-DICHLOROPHENYL)-5-IODO-3-METHYL-1-H-IMIDAZO[1,2-a]IMIDAZOL-2-ONE
WO2005037780A3 (en) Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2h-chromium-6-yl-derivatives and drugs containing said compounds
EP0711773A4 (en)
WO2002016322A3 (en) Process for the preparation of 2-aminoethylpyridines
WO2000051579A3 (en) Use of polycyclic thiazole systems for producing medicaments for preventing or treating obesity
WO2003039352A3 (en) Methods of reversing and preventing cardiovascular pathologies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP